source
- Kardigan targets $320 million IPO to fund three late-stage heart drugsKardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…
- Takeda’s oral psoriasis drug outperforms Bristol Myers’ Sotyktu in Phase 3 trialTakeda announced that its experimental oral medication for plaque psoriasis achieved superior results compared with Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. The trial measur…